Inventor
GEORGE YANCOPOULOS
Inventor
US
Overview
Patents· 5 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Kprimary
C07KPeptides33%
A61KPreparations for medical, dental or toiletry purposes27%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations27%
A01KAnimal husbandry7%
C12NMicroorganisms or enzymes7%
PatentTitleYear
12,127,537Genetically modified non-human animals and methods of use thereof202411,975,045Use of a VEGF antagonist to treat angiogenic eye disorders202411,730,794Use of a VEGF antagonist to treat angiogenic eye disorders202311,707,506Use of a VEGF antagonist to treat angiogenic eye disorders202311,253,572Use of a VEGF antagonist to treat angiogenic eye disorders2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2024Patents assigned to REGENERON PHARMA (5)· patent assignee history
2022–2024Based in US· patent location history
2023Patents assigned to REGENEREN PHARMACEUTICALS INC (1)· patent assignee history
2024Patents assigned to INSTITUTE FOR RES IN BIOMEDICINE IRB (1)· patent assignee history
2024Patents assigned to UNIV YALE (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| REGENERON PHARMA | 5 | 2022–2024 |
| INSTITUTE FOR RES IN BIOMEDICINE IRB | 1 | 2024 |
| REGENEREN PHARMACEUTICALS INC | 1 | 2023 |
| UNIV YALE | 1 | 2024 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 5 | 2022–2024 |